164 related articles for article (PubMed ID: 11250716)
1. Mammographic screening and mammographic patterns.
Day N; Warren R
Breast Cancer Res; 2000; 2(4):247-51. PubMed ID: 11250716
[TBL] [Abstract][Full Text] [Related]
2. Mammographic screening and mortality from breast cancer: the Malmö mammographic screening trial.
Andersson I; Aspegren K; Janzon L; Landberg T; Lindholm K; Linell F; Ljungberg O; Ranstam J; Sigfússon B
BMJ; 1988 Oct; 297(6654):943-8. PubMed ID: 3142562
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study.
Cuzick J; Warwick J; Pinney E; Duffy SW; Cawthorn S; Howell A; Forbes JF; Warren RM
J Natl Cancer Inst; 2011 May; 103(9):744-52. PubMed ID: 21483019
[TBL] [Abstract][Full Text] [Related]
4. Does the proven benefit of mammography extend to breast cancer patients over age 70?
Hwang ES; Cody HS
South Med J; 1998 Jun; 91(6):522-6. PubMed ID: 9634112
[TBL] [Abstract][Full Text] [Related]
5. Mammographic Density Reduction as a Prognostic Marker for Postmenopausal Breast Cancer: Results Using a Joint Longitudinal-Survival Modeling Approach.
Andersson TM; Crowther MJ; Czene K; Hall P; Humphreys K
Am J Epidemiol; 2017 Nov; 186(9):1065-1073. PubMed ID: 28633324
[TBL] [Abstract][Full Text] [Related]
6. Mammographic density reduction is a prognostic marker of response to adjuvant tamoxifen therapy in postmenopausal patients with breast cancer.
Li J; Humphreys K; Eriksson L; Edgren G; Czene K; Hall P
J Clin Oncol; 2013 Jun; 31(18):2249-56. PubMed ID: 23610119
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen, mammographic density, and breast cancer prevention.
Boyd NF
J Natl Cancer Inst; 2011 May; 103(9):704-5. PubMed ID: 21487099
[No Abstract] [Full Text] [Related]
8. Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years.
Brentnall AR; Warren R; Harkness EF; Astley SM; Wiseman J; Fox J; Fox L; Eriksson M; Hall P; Cuzick J; Evans DG; Howell A
Breast Cancer Res; 2020 Sep; 22(1):101. PubMed ID: 32993747
[TBL] [Abstract][Full Text] [Related]
9. Mammographic Density as a Biosensor of Tamoxifen Effectiveness in Adjuvant Endocrine Treatment of Breast Cancer: Opportunities and Implications.
Mullooly M; Pfeiffer RM; Nyante SJ; Heckman-Stoddard BM; Perloff M; Jatoi I; Brinton LA; Aiello Bowles EJ; Hoover RN; Glass A; Berrington de Gonzalez A; Sherman ME; Gierach GL
J Clin Oncol; 2016 Jun; 34(18):2093-7. PubMed ID: 27022110
[No Abstract] [Full Text] [Related]
10. A simulation model investigating the impact of tumor volume doubling time and mammographic tumor detectability on screening outcomes in women aged 40-49 years.
Bailey SL; Sigal BM; Plevritis SK
J Natl Cancer Inst; 2010 Aug; 102(16):1263-71. PubMed ID: 20664027
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer screening by mammography in women aged under 50 years in Japan.
Morimoto T; Sasa M; Yamaguchi T; Kondo H; Akaiwa H; Sagara Y
Anticancer Res; 2000; 20(5C):3689-94. PubMed ID: 11268440
[TBL] [Abstract][Full Text] [Related]
12. Effects of age, breast density, ethnicity, and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: review of 183,134 screening mammograms in Albuquerque, New Mexico.
Rosenberg RD; Hunt WC; Williamson MR; Gilliland FD; Wiest PW; Kelsey CA; Key CR; Linver MN
Radiology; 1998 Nov; 209(2):511-8. PubMed ID: 9807581
[TBL] [Abstract][Full Text] [Related]
13. Relationship between mammographic breast density and tamoxifen in women with breast cancer.
Tiersten A; Ng YY; Pile-Spellman E; Nelsen C; Noguera-Irizarry W; Brafman R; Russo D; Troxel A; Johnson A
Breast J; 2004; 10(4):313-7. PubMed ID: 15239789
[TBL] [Abstract][Full Text] [Related]
14. Benefits of screening mammography: a review for the primary care physician.
Reichle JL
South Med J; 1998 Jun; 91(6):510-7. PubMed ID: 9634110
[TBL] [Abstract][Full Text] [Related]
15. Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women.
Decensi A; Robertson C; Guerrieri-Gonzaga A; Serrano D; Cazzaniga M; Mora S; Gulisano M; Johansson H; Galimberti V; Cassano E; Moroni SM; Formelli F; Lien EA; Pelosi G; Johnson KA; Bonanni B
J Clin Oncol; 2009 Aug; 27(23):3749-56. PubMed ID: 19597031
[TBL] [Abstract][Full Text] [Related]
16. Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades.
Tabár L; Vitak B; Chen TH; Yen AM; Cohen A; Tot T; Chiu SY; Chen SL; Fann JC; Rosell J; Fohlin H; Smith RA; Duffy SW
Radiology; 2011 Sep; 260(3):658-63. PubMed ID: 21712474
[TBL] [Abstract][Full Text] [Related]
17. Spectrum of mammographically detected breast cancers.
Sener SF; Winchester DJ; Winchester DP; Kurek R; Motykie G; Martz CH; Rabbitt S
Am Surg; 1999 Aug; 65(8):731-5; discussion 735-6. PubMed ID: 10432082
[TBL] [Abstract][Full Text] [Related]
18. Effect of tamoxifen on breast tissue density in premenopausal breast cancer.
Slanetz PJ; Grandpre LE; Yeh ED; Kopans DB; Mendel JB
Breast J; 2004; 10(1):27-32. PubMed ID: 14717756
[TBL] [Abstract][Full Text] [Related]
19. Mammographic density is related to stroma and stromal proteoglycan expression.
Alowami S; Troup S; Al-Haddad S; Kirkpatrick I; Watson PH
Breast Cancer Res; 2003; 5(5):R129-35. PubMed ID: 12927043
[TBL] [Abstract][Full Text] [Related]
20. Performance of a subsidised mammographic screening programme in Malaysia, a middle-income Asian country.
Lee M; Mariapun S; Rajaram N; Teo SH; Yip CH
BMC Public Health; 2017 Jan; 17(1):127. PubMed ID: 28129762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
